Welcome to our dedicated page for EVOMMUNE SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. reported that Chief Financial Officer Kyle Carver received an employee stock option grant. The award covers 98,946 shares of common stock at an exercise price of $26.77 per share and expires on April 15, 2036.
According to the vesting terms, one fourth of the option vests on the first anniversary of the grant, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 98,946 derivative securities directly.
Evommune, Inc. reported that Chief Business & Legal Officer Gregory S. Moss received an option grant for 115,279 shares of common stock at an exercise price of $26.77 per share. The options expire on April 15, 2036 and represent his entire reported option position from this grant.
According to the vesting terms, one fourth of the shares will vest on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter, subject to his continuous service with the company.
Evommune, Inc. President & CEO Luis C. Pena received a grant of employee stock options covering 291,420 shares of common stock. The options have an exercise price of $26.7700 per share and expire on April 15, 2036. Following this grant, he holds 291,420 derivative securities related to this award.
According to the vesting schedule, one quarter of the options vests on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments, subject to his continuous service. This is a compensation-related award rather than an open-market purchase or sale.
Evommune, Inc. has filed a resale registration covering up to 4,494,279 shares of common stock that may be sold from time to time by existing selling stockholders. The company will not receive proceeds from these resales, though it previously raised capital by privately selling these shares at $27.88 each.
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with Phase 2 programs EVO756 and EVO301 targeting conditions such as chronic spontaneous urticaria, atopic dermatitis, ulcerative colitis and migraine. As an emerging growth and smaller reporting company, it uses scaled reporting, retains earnings to fund growth and does not expect to pay dividends.
Evommune, Inc. furnished a webcast presentation describing the migraine treatment landscape and the scientific rationale for targeting the receptor MRGPRX2 with its oral small-molecule candidate EVO756. The materials outline how mast cells and sensory neurons may drive migraine and position MRGPRX2 inhibition as a potential new preventive approach.
The company highlights EVO756’s development roadmap across multiple inflammatory indications and its plan to initiate a Phase 2b, dose-ranging migraine prophylaxis trial in mid-2026. The presentation also notes high unmet need in migraine prevention, ongoing reliance on legacy preventives, and limitations of current CGRP-based therapies.
Evommune, Inc. is a clinical-stage biotechnology company focused on therapies for chronic inflammatory diseases, initially chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its strategy is to target key immune pathways driving mast cell activation, neuroinflammation and cytokine signaling.
The lead oral candidate EVO756 is a highly selective MRGPRX2 antagonist designed to modulate both mast cells and peripheral sensory neurons. Phase 1 data in 132 healthy volunteers showed it was well-tolerated with no serious adverse events and robust pharmacodynamic target engagement in an icatibant-induced skin wheal model. A Phase 2 CIndU trial in 30 patients with symptomatic dermographism showed 70% of 27 observed patients improved on FricTest at four weeks, 30% achieved complete response, and clinically meaningful itch reductions, with no serious adverse events. Phase 2b dose‑ranging trials in CSU and moderate‑to‑severe AD are ongoing, with 12‑week treatment and UAS7 or EASI as primary endpoints.
The second clinical candidate EVO301, in‑licensed from AprilBio, is a long-acting SAFA‑IL‑18 binding protein fusion targeting the IL‑18 pathway. A Phase 2a trial in 70 adults with moderate‑to‑severe AD using two intravenous doses met its primary endpoint, showing clinically meaningful activity and statistically significant improvement over placebo at weeks 4, 8 and 12. Evommune plans a subcutaneous Phase 2b trial in AD and is evaluating additional IL‑18–driven indications such as UC, Crohn’s disease and cardiovascular inflammatory conditions. The company is also preparing a Phase 2b trial of EVO756 in migraine and is advancing preclinical programs in other immunology and inflammation indications.
Evommune, Inc. reported fourth quarter and full year 2025 results and highlighted major clinical and financing milestones. Revenue reached $13.0 million for 2025, up from $7.0 million in 2024, driven by a licensing collaboration for EVO756 in Japan. Research and development expenses were $74.0 million and general and administrative expenses were $20.0 million, leading to a full year net loss of $68.9 million.
As of December 31, 2025, cash, cash equivalents and investments totaled $216.7 million, and together with a subsequent $125 million private placement in February 2026, are expected to fund operations through 2028. The company reported positive Phase 2a proof‑of‑concept data for EVO301 in atopic dermatitis, with meaningful EASI improvements and a favorable safety profile, and is planning a Phase 2b, Phase 3‑enabling trial. Oral MRGPRX2 antagonist EVO756 is in Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis, with top‑line data expected in the second quarter and second half of 2026, and a migraine trial planned for mid‑2026.
Evommune, Inc. received a new investment from LSP 7 through a February 2026 private placement. The company sold 4,494,279 common shares at $27.88 per share to institutional investors, including LSP 7, raising additional equity capital.
LSP 7 purchased 358,680 shares for total consideration of $9,999,998.40 and now beneficially owns 5,288,313 Evommune shares, representing about 14.7% of the 36,018,372 shares outstanding after the closing. LSP 7 Management B.V., a Netherlands entity, is the sole director of LSP 7.
In connection with the transaction, Evommune agreed to file a Form S-1 registration statement to register the resale of the private placement shares within 60 days of the February 17, 2026 closing and to use reasonable best efforts to keep that registration effective until the shares can be freely resold.
Evommune, Inc. director and 10% owner LSP 7 Cooperative UA, through its affiliated entity, acquired 358,680 shares of Common Stock as a grant or award on February 17, 2026 at $27.88 per share. Following this transaction, LSP 7 reported holding 5,288,313 shares indirectly. The shares are held of record by LSP 7 Cooperatief UA, with LSP 7 Management B.V. as sole director; its managing directors may be deemed to share beneficial ownership but each disclaims beneficial ownership of these shares.
Evommune, Inc. reported an insider-related equity award involving an affiliated investment entity. On February 17, 2026, LSP 7 Cooperatief U.A., an entity associated with director and 10% owner Felice Isabel Verduyn-van Weegen, acquired 358,680 shares of common stock at $27.88 per share through a grant or award. Following this transaction, the entity held 5,288,313 common shares indirectly attributed to the reporting person, who disclaims beneficial ownership except to the extent of any pecuniary interest.